Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 plus chemotherapy versus placebo plus chemotherapy for first-line CLDN18.2-positive advanced pancreatic cancer
CTR20252978Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QLS-31905 in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by Qilu Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
QLS-31905
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20252978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252978.